HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy (CT) in early breast cancer (BC) patients
Lucia Del Mastro(Ospedale Policlinico San Martino), Roberta Rosso(University of Catania), Paolo Bruzzi(Alleanza Contro il Cancro), Giovanna Cavazzini(University of Padua), B. Castagneto(Azienda Ospedaliera Carlo Poma), Franco Testore(Ente Ospedaliero Ospedali Galliera), M. Venturini, A. Contu(Ente Ospedaliero Ospedali Galliera), L Gallo, A Lavarello(Azienda Sanitaria Locale di Asti)
Cited by 4
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Trends and challenges in the operation of pumped-storage hydropower plants
|Renewable and Sustainable Energy Reviews|2015|315
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
A new generation of small hydro and pumped-hydro power plants: Advances and future challenges
|Renewable and Sustainable Energy Reviews|2014|273